Plasma Therapy 'ItansfusThchnoll987; 8:91-106

PLASMA THERAPYVolume 7, 1986

Subject Index

91

Index

ABSTRACTS6,409

ACQillRED IMMUNE DEFICIENCYSYNDROME

and infection control in hemapheresisunits. [Braine],259.

and Kaposi's sarcoma. extracorporealon­line perfusion of plasma over immobi­lized protein A as an immunomodula­tory therapy in patients with (Abstract)[Kiprov], 419.

and Kaposi's sarcoma with the Prosor-baTM protein A column. preliminaryobservations of off-line treatment of pa­tients with (Abstract) (Bertram), 414.

are apheresis personnel at risk for (Vogt,et all, 515.

in Chicago. prevalence of antibody toHTLV-ID and immunologic status ofhomosexual men without (Goldsmith,et all, 253.

in multitransfusedpatients withthalassemia major. risk of [Politis, etal),41.

in the United Kingdom (Weller), 23.

ACUTE NONLYMPHOCYTIC LEUKEMIAsee LEUKEMIA, ACUTE NONLYM­

PHOCYTIC

ADULT LEUKEMIAsee LEUKEMIA, ADULT

AGGLUTINATIONplatelet, in vitro obstructing flow during

plasma exchange (Freedman, et all, 231.

AGGLUTINATION, SOYBEANand sheep red blood cell rosetting in

adult leukemia. physical Tcell removalfrom allogeneic bone marrow: resultsusing [Slocombe, et all, 97.

AIDSsee ACQillRED IMMUNE DEFICIENCY

SYNDROME

ALBUMIN HYPERSENSITIVITYmaintenanceplasma exchange using

hydroxyethyl starch replacement in apatient with (Abstract) (Burgstaler &Pineda), 416.

ALLOGENEIC BONE MARROWsee BONE MARRO\¥, ALLOGENEIC

ALLOGENEIC BONE MARROW TRANS­PLANTATION

see TRANSPLANTATION, AL­LOGENEIC BONE MARROW

ALLOGENEIC BONE MARROW TRANS­PLANTATION, T-CELL DEPLETEDHLA-MATCHED

see TRANSPLANTATION, AL­LOGENEIC BONE MARRO\¥, T-CELLDEPLETED HLA-MATCHED

AMERICAN SOCIETY FOR APHERESISSEVENTH ANNUAL SYMPOSIUM,Chicago, 1985. Proceedings

249.

ANAPHYLA10XIN INFORMATIONin apheresis procedures (Abstract) (Pfaeffi

& Kiprov), 421.

92 Plasma Therapy Vol. 8, No. 1

ANEMIC PATIENTSa simple technique for safe

discontinuous-flow therapeuticcytapheresis in (Brief Report), (Valbone­si, et all, 237.

ANTIBODIES, MONOCLONALand complement in autologous bone mar­

row transplantation.elimination of leu­kernic cells with (Campana, et all, 83.

anti-A, anti-B (Abstract) [Messeter], 15.

in vivo or in vitro? (Hamblin), 437.

ANTI ·GLOMERULAR BASEMENTMEMBRANE DISEASE

plasma exchange in [Lloveras, et all, 123.

ANTI-IDIOTYPESidiotypes, and autoimmune disease

(Cooke), 161.

systemic lupus erythematosus: idiotypesand [Isenberg], 171.

see also IDIOTYPES

ANTITHROMBIN illin the thrombotic complications of plas­

ma exchange. the role of platelet actiovation and (Abstract) (Silberstein, et all,415.

APHERESISAmerican Society for Seventh Annual

Symposium, Chicago, 1985.Proceedings

and national involvement. growth in(Miller), 299.

donor/patient managementusing Haemo­netics Model 30 and Fenwal CS·3000blood cell separators (Mitchum), 311.

in rheumatoid arthritis (Yarboro), 265.

on the Haemonetics v-so. quality controlof platelets from platelet-rich plasmaharvested by (Salusinsky-Sternbach),219.

APHERESIS, CENTRIFUGALpilot studies on a new machine for (Gil­

lon, et all, 45.

APHERESIS, PLATELETon the COBE 2997 (IBM) blood cell sepa­

rator. effective (Smith), 395.

APHERESIS, SINGLE-DONORstorage of platelet concentratesobtained

from (Rock), 485. .

APHERESIS DONORS, POTENTIALrecruiting to increase HLA donor base

(Abstract) (Sterba, et all, 420.

APHERESIS PERSONNELat risk for AIDS?(Vogt, et all, 515.

APHERESIS PROCEDURESanaphylatoxininformationin (Abstract)

[Pfaeffl& Kiprov), 421.

donor assessment and quality control of(Summers), 329.

donor motivation and recruitment for(Robinson), 477.

APHERESIS SYSTEMthe Haemonetics VSO (Halpern), 405.

APHERETIC THERAPYin symptomatic cryoglobulinemia: efflca­

cy and comparison of centrifugalandcascade filtration systems in a cross­over study (Valbonesi, et all, 111.

AUIDIMMUNE DISEASEidiotypes, anti-idiotypes, and (Cooke),

161.

AUIDLOGOUS, ALLOACTIVATEDHELPER-ENRICHEDLYMPHOCYTES

see LYMPHOCYTES, AUIDLOGOUS,ALLOACTIVATED HELPER­ENRICHED

AUIDLOGOUS BONE MARROW TRANS­PLANTATION

see TRANSPLANTATION, AUIDLO­GOUS BONE MARROW

AUIDMATED DONOR SYSTEMSplasmapheresiscomparative study of four

new (Coffe, et all, 49.

AUTOTRANSFUSIONautotransfusion(Abstract) (Sachs), 20.

BLOOD BANKINGquality control in (Abstract) (Wagstaff), 6.

BLOOD CELL SEPARATORsee CELL SEPARATOR, BLOOD

BLOOD COAGULATIONand transfusion.the impact of recombinant

DNA technology in (Giddings), 493.

BLOOD FLOW RATEeffects of whole, on efficiency of ex­

change and patient morbidity in mem­brane plasmapheresis (Abstract)(Andrews et all, 409.

BLOOD MANIPULATION,EXTRACORPOREAL

extracorporealblood manipulation(Ab­stract) (Heustis), 10.

BLOOD PLASMAsee PLASMA, BLOOD

BLOOD SUBSTITUTES, OXYGEN­CARRYING

oxygen-carrying blood substitutes (Ab­stract) (Lutz), 17.

BLOOD TRANSFUSION SERVICESlong-rangeplanning and alternative fu­

tures for (Abstract) (Brodheim), 6.

BLOOD TRANSFUSIONSsee TRANSFUSIONS, BLOOD

BONE MARRO\v, ALLOGENEICphysical Tcell removal from: results us­

ing soybean agglutinationand sheepred blood cell rosetting in adult leuke­mia (Slocombe, et all, 97.

BONE MARROW PROCESSINGand ex vivo purging prior to allogeneic

and autologous bone marrow transplan­tation (Herve & Andrew), 455.

technique using the Fenwal CS-3000. de­velopment and analysis of a fully auto­mated (Abstract) (Lasky, et all, 424.

BONE MARROW TRANSPLANTATIONsee TRANSPLANTATION, BONE

MARROW

BREAST CANCER, ADVANCEDtreatment of, with ProsorbaTM protein A

columns (Abstract) (Messerschmidt),419.

BRIEF REPORTS237.

CANCER,COLORECTALsee COLORECTAL CANCER

CANCER OF THE LARYNXtemporary restoration of immune

Index 93

response and tumor regression follow­ing plasmapheresis in a patient withadvanced (Abstract) (Seder, et all, 417.

CASCADE FILTRATION SYSTEMSsee FILTRATION SYSTEMS,CASCADE

CELL COLLECTION/DEPLETIONby continuous flow centrifugation(CFC).

a model for (Abstract) (Hester), 422.

CELL SEPARATIONSthe effect of hematocrit and recycle on

(Van Wie & Hustvedt), 373.

CELL SEPARAIDR, BLOODeffective platelet apheresis on the COBE

2997 (lliM) (Smith), 395.

apheresis donor/patient management us­ing Haemonetics Model 30 and FenwalCS-3000 (Mitchum), 311.

CELLULAR IMMUNITYsee IMMUNITY, CELLULAR

CENTRAL VENOUS THROMBOSISsee THROMBOSIS, CENTRAL VENOUS

CENTRIFUGAL APHERESISsee APHERESIS,CENTRIFUGAL

CENTRIFUGAL ELUTRIATIONcentrifugal, elutriation (Monroy), 389.

CENTRIFUGAL FILTRATION SYSTEMSsee FILTRATION SYSTEMS, CEN­

TRIFUGAL

CENTRIFUGAL SEPARATIONsee SEPARATION, CENTRIFUGAL

CENTRIFUGATION,CONTINUOUS-FLOW

a model for cell collection/depletion by(Abstract) (Hester), 422.

CERTIFICATIONfor hemapheresis specialists (Mallard),

305.

CHURG-STRAUSS SYNDROME, SEVEREtreatment of with plasma exchange [Clut­

terbuck, et all, 117.

CIRCULATING GRANULOCYTE­MACROPHAGE PRECURSORS

see GRANULOCYTE·MACROPHAGEPRECURSORS, CIRCULATING

94 Plasma Therapy Vol. 8, No. 1

CIRCULATING IMMUNE COMPLEXESand immunoglobulin-G, selective ex­

tracorporealremoval of: a review(Jones, et al), 333.

COLD AGGLUTININ DISEASEplasmapheresis in (Abstract) (An­

drzejewski, et all, 417.

COLLOID DEPLETIONand pleural effusion after plasmapheresis

in Waldenstrom's macroglobulinemia(Abstract) (Seder & Karlinsky), 415.

COLORECTAL CANCERwith staphylococcal protein A. treatment

of advanced (Abstract) (Fiore), 413.

COMPLEMENTin autologous bone marrow transplanta­

tion. elimination of leukemic cellswith monoclonal antibodies and (Cam­pana, et all, 83.

CONTINUOUS-FLOWCENTRIFUGATION

see CENTRIFUGATION,CONTINUOUS-FLOW

CORONARY ARTERY BYPASSG~G,EMERGENCY

heparin-associatedthrombocytopenia in apatient requiring (Abstract) (Silverman,et all, 418.

CORRECTIONS244.

CRYOGLOBULINEMIA, SYMProMATICapheretic therapy in: efficacy and com­

parison of centrifugaland cascadefiltration systems in a crossover study(Valbonesi, et all, 111.

CYCLOSPORIN Aand plasmapheresis (PE) in severe cases

of systemic lupus erythematosus (SLE)(Abstract) (Bambauer, et all, 419.

CYTAPHERESISthe isolation of humanmononuclearleu­

kocyte subsets by, for laboratoryresearch (Stevenson, et all, 365.

transfusionof autologous, alloactivatedhelper-enrichedlymphocytes obtainedby to patients with melanoma (Sciorel­u, et all, 469.

CYTAPHERESIS, DISCONTINUOUS­FLOW THERAPEUTIC

in anemic patients. a simple techniquefor safe (Brief Report], (Valbonesi, et all,237.

CYTAPHERESIS PROCEDURESinfluence of number and frequency of, on

donors' lymphocyte count (Le Francois,et all, 67.

CYTOTOXIC THERAPYin scleroderma. plasmapheresis plus

steroidand (Abstract) (Ward & Kaplan),416.

DEVELOPING COUNTRIESblood transfusionin (Abstract) [Leikola],

19.

DISCONTINUOUS-FLOW THERAPEUTICCYTAPHERESIS

see CYTAPHERESIS, DISCONTINUOUS·FLOWTHERAPEUTIC

DONORplasmapheresis systems. comparative

study of four new (Abstract) (Coffe, etal),422.

DONOR ASSESSMENTand quality control of apheresis proce­

dures (Summers), 329.

DONOR MOTIVATIONand recruitment for apheresis procedures

(Robinson),477.

DONOR/PATIENT MANAGEMENTusing Haemonetics Model 30 and Fenwal

CS-3000 blood cell separators (Mitch­um),311.

DONORS, APHERESIS, POTENTIALsee APHERESISDONORS, POTENTIAL

DRUG REMOVALby plasma exchange (Abstract) (Lake, et

al),415.

EDIIDRIALHamblin, 'IerenceJ., 21Hamblin, 'ThrenceJ., 159.

ELUTRIATION, CENTRIFUGALsee CENTRIFUGAL ELUTRlATION

ERYTHROCYTAPHERESISa new effective tool for treatment of cen­

tral venous thrombosis of the eye

[Spengel & Zoller), 139.

EUROPEAN SOCIETY FORHAEMAPHERESIS

future activities of (Valbonesi), 555.

EUROPEAN SOCIETY FORHAEMAPHERESIS,3rd ANNUALMEETING, Boumemouth, 1985.Proceedings

21.

EXTRACORPOREAL BLOODMANIPULATION

see BLOOD MANIPULATION, EX­TRACORPOREAL

EXTRACORPOREAL ON-LINEPERFUSION

of plasma over immobilized Protein A asan immunomodulatory therapy in pa­tients with AIDS and Kaposi's sarcoma(Abstract) (Kiprov), 419.

EXTRACORPOREALSELECTnffiREMOVAL

of immunoglobulinand circulating im­mune complexes: a review (Jones, etal),333.

EYESerythrocytapheresis, a new effective tool

for treatment of central venous throm­bosis of the (Spengel & Zoller), 139.

FAMILIAL HYPERCHOLESTEROLEMIAsee HYPERCHOLESTEROLEMIA,

FAMILIAL

FffiRONECTINfibronectin (Abstract) [Lundsgaard­

Hansen), 14.

FILTER SYSTEM, FLATSHEETAutopheresis-C. quality control of blood

plasma harvested by (Nydegger &P£1ugshaupt), 52.

FILTRATION SYSTEMevaluation of new OrganonTeknika plas­

ma exchange (Abstract) (Coffe, et all,410.

FILTRATION SYSTEMS, CASCADEand centrifugal filtration systems in a

crossover study. apheretic therapy insymptomatic cryoglobulinemia: efficacyand comparison of (Valbonesi, et all,111.

Index 95

FILTRATION SYSTEMS, CENTRIFUGALand cascade filtration systems in a cross­

over study. apheretic therapy in symp­tomatic cryoglobulinemia: efficacy andcomparison of (Valbonesi, et all,111.

FLAT SHEET FILTER SYSTEMsee FILTER SYSTEM, FLAT SHEET

FLOWduring plasma exchange. platelet aggluti­

nation in vitro obstructing (Freedman,et all, ~1.

GLOMERULONEPHRITIS,MESANGIO­CAPILLARY

with nomal renal function followingplasma exchange. persistent improve­ment of proteinuriain (Abstract) (Rad­wan, et all, 412.

GRANULOCYTE CONCENTRATES,ISOLATION OF

analysis of results of three differentmethods for platelet and-practicalandeconomic considerations (Osterwalder,et all, 61.

GRANULOCYTE-MACROPHAGEPRECURSORS, CIRCULATING

in patients with acute nonlymphocyticleukemia. collection of (Reiffers, et all,93.

GUILLAIN-BARRE SYNDROMEmembrane separatorplasmapheresis in

(Abstract) (Zakheim, et all, 425.

HAEMAPHERESISEuropeanSociety for, 3rd Annual Meet­

ing, Boummouth, 1985. Proceedings.21.

future activities of the EuropeanSocietyfor [Valbonesi], 555.

twenty years of: a technical gadget growsinto a therapeutic tool [Borberg], 435.

HEMAPHERESISSPECIALISTScertification for (Mallard), 305.

HEMAPHERESISUNITSthe acquired immune deficiency syn­

drome and infection control in (Braine),259.

HEMAIDCRITand recycle on cell separations. the effect

96 Plasma Therapy Vol. 8, No. 1

of [Van Wie & Hustvedt), 373.

HEPARIN-ASSOCIATEDTHROMBOCYroPENIA

see THROMBOCYroPENIA, HEPARIN­ASSOCIATED

HEPATITIS VIRUSESin plasma derivatives. inactivation of (Ab­

stract) (prince), 8.

HOMOSEXUAL MENwithout AIDS in Chicago. prevalence of

antibody to HTLv-m and immunologicstatus of (Goldsmith, et all, 253.

HTLv-mand immunologic status of homosexual

men without AIDS in Chicago. preva­lence of antibody to (Goldsmith, et all,253.

HUMAN IMMUNODEFICIENCYVIRUSINFECTION

see IMMUNODEFICIENCYVIRUS IN·FECTION, HUMAN

HYDROXYETHYLSTARCHREPLACEMENT

in a patient with albumin hypersensitivi­ty. maintenanceplasma exchange using(Abstract)IBurgstaler& Pineda), 416.

HYPERCHOLESTEROLEMIA, FAMILIALLDL-elimination by a 'combination of

plasma separation and plasma filtrationin (Abstract) [Dernant, et all, 425.

IDlarYPE-ANTI-IDlOTYPE NETWORKsee NETWORK, IDIOTYPE-ANTI­

IDIOTYPE

IDIOTYPESand anti-idiotypes, systemic lupus

erythematosus (Isenberg), 171.

anti-idiotypes, and autoimmune disease(Cooke), 161.

see also ANTI·IDIOTYPES

IDIOTYPES, SlnRFACEof lymphoma. therapeutic attack on

(Stevenson), 203.

IDlarYPlC NETWORKsee NETWORK, IDIOTYPIC

IgM PARAPROTEIN POLYNEUROPATHY

see POLYNEUROPATHY, IgMPARAPROTEIN

IMMUNE COMPLEXES, CIRCULATINGsee CIRCULATING IMMUNE COM­

PLEXES

IMMUNE COMPLEXES, DETECTION OFpresent in blood. improved method for

quantitationand (Abstract) [Sterhan],420.

IMMUNE COMPLEXES,QUANTITATION OF

present in blood . improved method fordetection and (Abstract) (Sterhan), 420.

IMMUNE RESPONSEand tumor regression following plas­

mapheresis in a patient with advancedcancer of the larynx. temporary resto­ration of (Abstract) (Seder, et all, 417.

IMMUNITY, CELLULARimpact of large volume plasmapheresis

on (Bonomini, et all, 451.

IMMUNOADSORPTIONplasma perfusion and (Pineda), 443.

selective removal of low densitylipoprotein in patients using (Gordon,et all, 359.

IMMUNOADSORPTION,EXTRACORPOREAL

with Prosorba™ columns. treatment oflymphosarcoma (LSA) in pet cats by(Abstract) (Shelton & Jones), 412.

IMMUNODEFICIENCYVIRUSINFECTION, HUMAN

inflammatory demyelinating poly­neuropathies in (Cornblath, et all, 521.

IMMUNOGLOBULIN ADJUVANTTHERAPY

to plasmapheresis in immunopathologi·cal disorders (Nydegger), 197.

IMMUNOGLOBULIN-Gand circulating immune complexes,

selective extracorporealremoval of: areview IJones, et all, 333.

IMMUNOGLOBULINSthe therapeutic use of-clinical trials and

future goals (Abstract) [Diecher],12.

IMMUNOGLOBULINS, EXTENSIVEREMOVAL

a summary of five years' clinicalexperience with [Preiburghaus,et al],545.

IMMUNOGLOBULINS, INTRAVENOUSintravenous immunoglobulins (Abstract)

(Nydegger), 13.

IMMUNOPATHOLOGIC DISORDERSimmunoglobulinadjuvant therapy to

plasmapheresis in (Nydegger), 197.

INFECTIONCONTROLin hemapheresis units. the acquired im­

mune deficiency syndrome and[Braine], 259.

INFLAMMAIDRY DEMYELINATINGPOLYNEUROPATHIES

see POLYNEUROPATHIES, INFLAMMA-IDRY DEMYELINATING

INTERNATIONAL SOCIETY OF BLOODTRANSFUSION, Munich, 1984.Proceedings.

(Highlights) (Hogman), 5.

INTRAVENOUS IMMUNOGLOBULINSsee IMMUNOGLOBULINS, IN­

TRAVENOUS

INTRODUCTION249,Hamblin, 433.

KAPOSI'S SARCOMAextracorporealon-line perfusion of plas­

ma over immobilized protein A asan immunomodulatory therapy in pa­tients with AIDS and (Abstract).[Kiprov], 419.

with the Prosorba" protein A column.preliminary observations of off-linetreatment of patients with AIDS and[Abstractl Bertram], 414.

LARGE VOLUME PLASMAPHERESISsee PLASMAPHERESIS/PLASMA EX­

CHANGE/LARGE VOLUME

LDL-ELIMINATIONby a combination of plasma separation

and plasma filtration in familial hyper­cholesterolemia (Abstract) [Demant, etal),425.

LEUKEMIA

Index 97

bone marrow transplantationfor (Barrett),71.

LEUKEMIA,ACUTEin first remission. T-cell depleted HLA­

matched allogeneic bone marrow trans­plantation in the treatment of (Pren­tice, et all, 77.

LEUKEMIA, ACUTE NONLYMPHOCYTICcollection of circulatinggranulocyte­

macrophage precursors in patients with[Reiffers, et al), 93.

LEUKEMIA, ADULTphysical T-cell removal from allogeneic

bone marrow: results using soybean ag­glutination and sheep red blood cellrosetting in [Slocombe, et al], 97.

LEUKEMIC CELLSwith monoclonal antibodies and comple­

ment in autologous bone marrow trans­plantation. elimination of (Campana, etal),83.

LEUKOCYTAPHERESIScase study (Jordan), 275.

LEUKOCYTE SUBSETS, HUMANMONONUCLEAR

see MONONUCLEAR LEUKOCYTESUBSETS, HUMAN

LIPOPROTEIN, LOW DENSITYin patients using immunoadsorption.

selective removal of (Gordon, et al],359.

LITERATURE UPDATE143,239.

LOW DENSITY LIPOPROTEINsee LIPOPROTEIN, LOW DENSITY

LUPUS ERYTHEMAIDSUS, SYSTEMICsee SYSTEMIC LUPUS

ERYTHEMAIDSUS

LUPUS ERYTHEMAIDSUS NEPHRITIS,SYSTEMIC

see SYSTEMIC LUPUS ERYTHEMAID­SUS NEPHRITIS

LUPUS NEPHRITISsee NEPHRITIS, LUPUS

LYMPHOCYTAPHERESISin the treatment of idiopathic pulmonary

fibrosis (IPF) (Abstract) (Fahey, et al],424.

98 Plasma Therapy Vol. 8, No. 1

LYMPHOCYTAPHERESIS, LONGTIRMin progressive multiple sclerosis (Rosen

& Hamburger), 227.

LYMPHOCYTE CONTAMINATIONof CS-3000 plate1etpheresis products.

rapid depletion of plasma from separa­tion chamber significantly reduces (Ab­stract) (Mintz, et all, 411.

LYMPHOCYTE COUNTinfluence of number and frequency of

cytapheresis procedures on donors'(LeFrancois, et all, 67.

LYMPHOCYTES, AUIDLOGOUS,ALLOACTIVATED HELPER·ENRICHED

transfusionof, obtained by cytapheresisto patients with melanoma (Sciorelli,et all, 469.

LYMPHOMAtherapeuticattack on surface idiotypes of

(Stevenson), 203.

LYMPHOSARCOMA(LSA) in pet cats by extracorporealim­

munoadsorptionwith Prosorba™columns. treatment of (Abstract) (Shel­ton & Jones), 412.

MALIGNANCYreport on toxicity. phase I clinical trial of

protein A [Prosorba" columns) in (Ab·stract) (Henry), 413.

MARROWsee BONE MARROW

MELANOMAtransfusionof autologous, alloactivated

helper-enrichedlymphocytes obtainedby cytapheresis to patients with(Sciorelli, et all, 469.

MEMBRANE PLASMAPHERESISsee PLASMAPHERESIS/PLASMA EX·

CHANGE, MEMBRANE

MEMBRANE SEPARAlDRplasmapheresis in Cuillain-Barresyn­

drome (Abstract) (Zakheim, et all, 425.

MESANGIOCAPILLARYGLOMERULONEPHRITIS

see GLOMERULONEPHRITIS, MESAN·GIOCAPILLARY

MONOCLONAL ANTIBODIESsee ANTIBODIES, MONOCLONAL

MONONUCLEAR LEUKOCYTESUBSETS, HUMAN

by cytapheresis for laboratory research.the isolation of (Stevenson, et al], 365.

MULTIPLESCLEROSIS, PROGRESSIVEsee PROGRESSIVE MULTIPLE

SCLEROSIS

MULTITRANSFUSED PATIENTSwith thalassemiamajor. risk of acquired

irnrnunedeficiency syndrome in [Poli­tis, et al), 41.

MYASTHENIA GRAVIScase study: plasma exchange therapy for

the patient with (Hunter), 271.

MYASTHENIA GRAVIS, HUMANevidence for the existence of an idiotype­

anti-idiotype network in (Lefvert), 187.

MYELOMA, POOR·PROGNOSISprolonged survival following plasma ex­

change in (Cotter & Newland), 133.

NEONATAL GRANULOCYTETRANSFUSIONS

see TRANSFUSIONS, NEONATALGRANULOCYTE

NEPHRITIS, LUPUSplasmapheresisin: a controlled study­

preliminary results (Abstract) (Wallace,et all, 418.

NEPHROLOGYplasma exchange in (Glockner & Sie­

berth), 541.

NETWORK, IDIOTYPICand renal disease (Savage), 177.

NETWORK, IDIOTYPE·ANTJ·IDIOTYPEin humanmyasthenia gravis. evidence for

the existence of an (Lefvert), 187.

NEUROLOGIC DISEASESselective removal of pathogenic factors in

(Heininger, et all, 351.

NEUROLOGIC DISORDERSrationale for plasma exchange in (Steck

& Barkas), 527.

OFF-LINETREATMENTof patients with AIDS and Kaposi's sarco­

ma with the Prosorba™ protein Acolumn. preliminary observations of(Abstract) (Bertram), 414.

OXYGEN-CARRYING BLOOD SUB­STITUTES

see BLOOD SUBSTITUTES, OXYGEN­CARRYING

PATHOGENIC FACTORSin neurologic diseases. selective removal

of (Heininger), 351.

PATIENT MANAGEMENTon the COBE 2997 (ffiM) (Muellenhagen),

319.

PATIENTS, MULTITRANSFUSEDsee MULTITRANSFUSED PATIENTS

PHARMACOKINETICS, PHENYTOINsee PHENYTOIN PHARMACOKINETICS

PHENYTOIN PHARMACOKINETICSin therapeuticplasmapheresis (Abstract)

(Nasca, et all, 409.

PLASMA, BLOODharvested by the flat-sheet filter system

autopheresis-C, quality control of(Nydegger & Pflugshaupt), 57.

PLASMA, PLATELET-RICHharvested by apheresis on the Haernonet­

ics V-50. quality control of plateletsfrom [Salusinsky-Sternbach& Paquin),219.

PLASMA DERIVATIVESinactivation of hepatitis viruses in (Ab­

stract) (Prince), 8.

PLASMA EXCHANGEsee PLASMAPHERESIS/PLASMA EX­

CHANGE

PLASMA FILTRATIONin familial hypercholesterolemia. LDL­

elimination by a combination of plas­ma separationand (Abstract) (Demant,et all, 425.

PLASMA FRACTIONATIONand machine plasmapheresis (Evans, et

al),33.

PLASMA PROfEIN FRACTIONStransmission of virus diseases by

(Horowitz & Piet], 503.

PLASMA SEPARATIONand plasma filtration in familial hyper­

cholesterolemia. LDL-elimination by acombination of (Abstract) [Demant, etal),425.

Index 99

PLASMAPERFUSIONand immunoadsorption(Pineda), 443.

PLASMAPHERESISIPLASMAEXCHANGEand cyclosporin A (CYA) in severe cases

of systemic lupus erythematosus (SLE)(Abstract) (Bambauer), 419.

as a new service in an urbanhospital.eighteen months'experience with (Ab­stract) (Wolf, et all, 414.

comparative study of four new automateddonor'systems (Coffe, et all, 49.

comparison of manual and machinemethods (Abstract) (Rock, et all, 421.

drug removal by (Abstract) (Lake, et all,415.

filtration system. evaluation of new Orga­non Teknika (Abstract) (Coffe, et all,410.

in a patient with advanced cancer of thelarynx. temporary restorationof im­mune response and tumor regressionfollowing (Abstract) (Seder, et all, 417.

in anti-glomerularbasement membranedisease [Lloveras, et all, 123.

in cold agglutinin disease (CAD) (Ab­stract) (Andrzejewski, et all, 417.

in Guillain-Barresyndrome. membraneseparator (Abstract) (Zakheim, et all,425.

in immunopathologicdisorders. im­munoglobulinadjuvant therapy to(Nydegger), 197.

in lupus nephritis: a controlled study­preliminary results (Abstract) (Wallace,et all, 418.

in nephrology (Glockner & Sieberth],541.

in neurologic disorders. rationale for(Steck & Barkas], 527.

in poor-prognosis myeloma. prolongedsurvival following (Cotter & Newland),133.

100 Plasma Therapy Vol. 8, No.1

in thrombotic thrombocytopenic purpura.role of (ItalianCooperative Group forthe Study of TIP), 551.

in Waldenstrom'smacroglobulinemia.col­loid depletion and pleural effusion after(Abstract) (Seder & Karlinsky], 415.

persistent improvement of proteinuriainmesangiocapillaryglomerulonephritis(MCGN) with normal renal functionfollowing (Abstract) (Radwan, et all,412.

plasma fractionationand machine (Evans,et all, 33.

platelet agglutinationin vitro obstructingflow during (Freedman, et all, 231.

plus steroid and cytotoxic therapy inscleroderma (Abstract) (Ward &Kaplan), 416.

reverses paresthesiasand pain in IgMparaproteinpolyneuropathy (Abstract)(Dawson; et all, 411.

risk factors associated with thrombosisfollowing (Hendrick), 213.

systems comparative study of four newdonor (Abstract) (Coffe, et all, 422.

Tcell subsets in systemic lupuserythematosus nephritis treated with(Fosella, et all, 127.

the role of platelet activation and anti­thrombin III (ATIII) in the thromboticcomplications of (Abstract) (Silberstein,et al), 415.

thrombotic thrombocytopenia with renalfailure: the effect of (Camba, et all,107.

treatment of severe Churg-Strausssyn­drome with [Clutterbuck, et all, 117.

PLASMAPHERESIS/PLASMA EXCHANGE,LARGE VOLUME

impact of on cellular immunity (Bono­mini, et al], 451.

PLASMAPHERESIS/PLASMA EXCHANGE,MAINTENANCE

using hydroxyethyl starch replacement ina patient with albumin hypersensitivi­ty (Abstract) (Burgstaler & Pineda), 416.

PLASMAPHERESISIPLASMAEXCHANGE,MEMBRANE

effects of whole blood flow rate on effi­ciency of exchange and patient mor­bidity in (Abstracts) (Andrews, et al],409.

PLASMAPHERESIS/PLASMA EXCHANGE,THERAPEUTIC

definite indications and rescue therapy inrheumaticdiseases (Guillevin), 533.

for thrombotic thrombocytopenic purpura[TfP] (Abstract) (Ambinder, et al], 417.

phenytoin pharmacokineticsin (Abstract)(Nasca, et all, 409.

therapeutic.plasma exchange (Abstract)(Rock),IO.

PLASMAPHERESIS/PLASMA EXCHANGETHERAPY

for the patient with myasthenia gravis.case study (Hunter), 271.

PLATELETagglutinationin vitro obstructing flow

during plasma exchange (Freedman, etal),231.

PLATELETACTIVATIONand antithrombinIII (ATIII) in the throm­

botic complications of plasma ex­change. the role of (Abstract)(Silberstein, et all, 415.

PLATELET APHERESISsee APHERESIS, PLATELET

PLATELETCONCENTRATESpreparationand storage of (Abstract)

(Wagstaff), 8.

PLATELET CONCENTRATES,ISOLATION OF

and granulocyte concentrates. analysis ofresults of three different methods forthe practical and economic considera­tions [Osterwalder, et all, 61.

PLATELET CONCENTRATES, SINGLEDONOR

collected with the new program of surgepump process on Haemonetics V50(Abstract) (Coffe, et all, 410.

PLATELETCONCENTRATES, SIDRAGEobtained from single-donor apheresis

(Rock), 485.

PLATELETIMMUNOLOGYplatelet immunology (Abstract) (Mueller­

Eckhardt), 17.

PLATELETTRANSFUSIONSsee TRANSFUSIONS, PLATELET

PLATELETTRANSFUSIONS, SINGLEDONOR

see TRANSFUSIONS, SINGLE-DONORPLATELET

PLATELET YIELDScontrol of: toward a standardunit of

platelets (Huestis), 295.

PLATELET-RICHPLASMAsee PLASMA, PLATELET-RICH

PLATELETPHERESIS,MECHANICALTECHNIQUES

an assessment of (Hart, et all, 287.

PLATELETPHERESIS,SINGLE ACCESSa comparison of Haemonetics v-so and

Fenwal CS-3000 (Abstract) (Vados, etal),423.

PLATELETPHERESISPRODUCTSrapid depletion of plasma from separation

chamber significantly reduces lympho­cyte contaminationof CS-3000 (Ab­stract) (Mintz, et all, 411.

PLATELETScontrol of platelet yields: toward a stan­

dard unit of (Huestis), 295.

from platelet-rich plasma harvested byapheresis on the Haemonetics V-so.quality control of (Salusinsky­Sternbach & Paquin), 219.

PLEURAL EFFUSIONafter plasmapheresis in Waldenstrom's

macroglobulinemia.colloid depletionand (Abstract) (Seder & Karlinsky), 415.

POLYNEUROPATIIY, IgM PARAPROTEINplasma exchange reverses paresthesias

and pain in (Abstract) (Dawson, et all,411.

POLYNEUROPATHIES, INFLAMMAIDRYDEMYELINATING

in humanimmunodeficiency virus infec­tion [Cornblath, et all, 521.

POOR-PROGNOSIS MYELOMAsee MYELOMA, POOR-PROGNOSIS

Index 101

PROCEEDINGS5,21,249.

PROGRESSIVE MULTIPLE SCLEROSISlong-term lymphocytapheresis in (Rosen

& Hamburger), 227.

PROTEIN Apreliminary observations of off-line treat­

ment of patients with AIDS and Kapo­si's sarcoma with the ProsorbaTM

(Abstract) (Bertram), 414.

(Prosorba!Mcolumns) in malignancy:report on toxicity-phase I clinical trialof (Abstract) (Henry), 413.

ProsorbaTM: structureand function (Ab­stract) (Balint & Hargreaves), 412.

treatment of advanced breast cancer withProsorbaTM (Abstract) (Messerschmidt),419.

PROTEIN A, IMMOBILIZEDextracorporealon-line perfusion of plas­

ma over as an immunomodulatorytherapy in patients with AIDS andKaposi' sarcoma (Abstract) [Kiprov],419.

PROTEIN A, STAPHYLOCOCCALtreatment of advanced colorectal cancer

with (Abstract) (Fiore), 413.

PROTEINURIAin mesangiocapillaryglomerulonephritis

(MCGN) with normal renal functionfollowing plasma exchange. persistentimprovement of (Abstract) (Radwan, etal),412.

PULMONARY FIBROSIS, IDIOPATHIClymphocytapheresis in the treatment of

(Abstract) (Fahey, et all, 424.

PURGING, EX VIVObone marrow processing and, prior to al­

logeneic and autologous bone marrowtransplantation(Herve & Andrew), 455.

QUALITY CONTROLin blood banking (Abstract) (Wagstaff), 6.

of apheresis procedures. donor assess­ment and (Summers), 329.

of blood plasma harvested by the flat­sheet filter system autopheresis-C(Nydegger & Pflugshaupt), 57.

102 Plasma Therapy Vol. 8, No.1

of platelets from platelet-rich plasma har­vested by apheresis on the Haemonet­ics V·50 (Salusinsky-Sternbach&.Paquin), 219.

RECOMBINANT DNA TECHNOLOGYin blood coagulation and transfusion. the

impact of (Giddings), 493.

RECRUITMENTand donor motivation for apheresis proce­

dures (Robinson), 477.

RECYCLEthe effect of hematocrit and, on cell sepa­

rations (Van Wie &. Hustvedt), 373.

RENAL DISEASEthe idiotypic network and (Savage), 177.

RENAL FAILUREthrombotic thrombocytopenia with: the

effect of plasmapheresis [Camba, et all,107.

RESCUE THERAPYin rheumaticdiseases. therapeuticplas­

ma exchange: definite indications(Guillevin), 533.

RHEUMATIC DISEASEStherapeuticplasma exchange: definite in­

dications and rescue therapy in(Guillevin), 533.

RHEUMA1DID ARTHRITISapheresis in (Yarboro) 265.

ROSEITING, SHEEP RED BLOOD CELLin adult leukemia. physical T-cell removal

from allogeneic bone marrow: resultsusing soybean agglutinationand(Slocombe, et al], 97.

SCLERODERMAplasmapheresis plus steroid and cytotoxic

therapy in (Abstract) (Ward&. Kaplan),416.

SELECTIVEREMOVALof low-density lipoprotein in patients us­

ing immunoadsorption(Gordon, et all,359.

of pathogenic factors in neurologic dis­eases (Heininger, et all, 351.

SELECTIVEREMOVAL,EXTRACORPOREAL

see EXTRACORPOREAL SELECTIVEREMOVAL

SEPARATION,CENTRIFUGALwith the Fenwal CS-3000 (Cullis), 403.

SEPARATION CHAMBERsignificantly reduces lymphocyte con­

tamination of CS-3000 plateletpheresisproducts. rapid depletion of plasmafrom (Abstract) (Mintz, et all, 411.

SINGLE·DONOR APHERESISsee APHERESIS,SINGLE-DONOR

SINGLE-DONOR PLATELETCONCENTRATES

see PLATELETCONCENTRATES, SIN·GLEDONOR

SOYBEAN AGGLUTINATIONsee AGGLUTINATION, SOYBEAN

STAPHYLOCOCCAL PROTEIN Asee PROTEIN A, STAPHYLOCOCCAL

STEROID THERAPYand cytotoxic therapy in scleroderma.

plasmapheresis plus (Abstract) (Ward&.Kaplan), 416.

SURGE PUMPprocess on Haemonetics V50. single

donor platelet concentratescollectedwith the new program of (Abstract)(Coffe, et all, 410.

SYSTEMIC LUPUS ERYTHEMA1DSUSidiotypes and anti-idiotypes (Isenberg),

171.

SYSTEMIC LUPUS ERYTHEMA1DSUS,SEVERE

plasmapheresis (PE) and cyclosporin A(CYA) in (Abstract) [Bambauer, etall,419.

SYSTEMIC LUPUS ERYTHEMA1DSUSNEPHRITIS

treated with plasma exchange. Tcell sub­sets in (Fosella, et all, 127.

T-CELL SUBSETSin systemic lupus erythematosus nephri­

tis treated with plasma exchange(Fosella, et all, 127.

T-CELLSphysical removal from allogeneic bone

marrow: results using soybean aggluti­nation and sheep red blood cell reset-

ting in adult leukemia [Slocombe, etal),97.

THALASSEMIA MAJORrisk of acquired immune deficiency syn­

drome in multitransfused patients with(politis, et all, 41.

THROMBOCYTOPENIAand the standarduses of platelet transfu­

sions. the risks of (Strauss), 279.

1HROMBOCYTOPENIA, HEPARIN­ASSOCIATED

in a patient requiringemergency coro­nary artery bypass grafting (Abstract)(Silverman, et all, 418.

1HROMBOCYTOPENIA, THROMBOTICwith renal failure: the effect of plas­

mapheresis (Camba, et all, 107.

1HROMBOCYTOPENIC PURPURA,1HROMBOTIC

role of plasma exchange in (ItalianCooperative Group for the Study ofTIP),551.

therapeuticplasma exchange for (Ab­stract) (Ambinder, et all, 417.

treatment of. first results of a controlledclinical trial (Henon), 101.

1HROMBOSISfollowing plasma exchange. risk factors

associated with (Hendrick), 213.

THROMBOSIS, CENTRAL VENOUSof the eye. erythrocytapheresis, a new ef­

fective tool for treatment of (Spengel &Zoller), 139.

THROMBOTIC COMPLICATIONSof plasma exchange. the role of platelet

activation and antithrombinill (ATIll)in the (Abstract) (Silberstein, et all,415.

1HROMBOTIC 1HROMBOCYTOPENIAsee THROMBOCYTOPENIA,

THROMBOTIC

1HROMBOTIC 1HROMBOCYTOPENICPURPURA

see THROMBOCYTOPENIC PURPURA,1HROMBOTIC

IDXlCITYphase I clinical trial of protein A

Index 103

[Prosorba'P'columns) in malignancy:report on (Abstract) (Henry), 413.

TRANSFUSIONof autologous alloactivated helper­

enriched lymphocytes obtained bycytapheresis to patients with melano­ma [Sciorelli, et all, 469.

the impact of recombinant DNA technol­ogy in blood coagulation and [Cid­dings), 493.

TRANSFUSION REACTIONS,NEAR-FATAL

to a neonatalgranulocyte transfusion(Abstract) (O'Connor,et all, 421.

TRANSFUSIONS, BLOODin developing countries (Abstract) [Leiko­

la), 19.

InternationalSociety of, Munich, 1984.Proceedings (Highlights) (Hogman), 5.

see also BLOOD TRANSFUSIONSERVICES

TRANSFUSIONS, NEONATALGRANULOCYTE

a near-fatalreaction to a (Abstract)(O'Connor), 421.

TRANSFUSIONS, PLATELETthe risks of thrombocytopenia and the

standarduses of (Strauss), 279.

TRANSFUSIONS, SINGLE-DONORPLATELET

random: pros and cons [Gmur], 463.

TRANSPLANTATION, ALLOGENEICBONE MARROW

and autologous bone marrow transplanta­tion. bone marrow processing and exvivo purging prior to (Herve & An­drew),455.

TRANSPLANTATION, ALLOGENEICBONE MARROvv, T-CELL DEPLETEDHLA-MAlCHED

in the treatment of acute leukemia infirst remission (Prentice, et all, 77.

TRANSPLANTATION, AUIDLOGOUSBONE MARROW

bone marrow processing and ex vivopurging prior to allogeneic and (Herve& Andrew), 455.

104 Plasma Therapy Vol. 8/ No.1

elimination of leukemic cells withmonoclonal antibodies and comple­ment in (Campana, et al], 83.

TRANSPLANTATION, BONE MARROWfor leukemia (Barrett), 71.

TREATMENT COLUMNSpreliminary observations of off-line treat­

ment of patients with AIDS and Kapo­si's sarcoma with the ProsorbaTMprotein A (Abstract) (Bertram), 414.

(ProsorbaTM) in malignancy: report ontoxicity. phase I clinical trial of proteinA (Abstract) (Henry), 413.

protein A ProsorbaTM: structureand func­tion (Balint & Hargreaves), 412.

treatment of advanced breast cancer withProsorbaTM protein A (Abstract) (Mes­serschmidt), 419.

treatment of advanced colorectal cancerwith staphylococcal protein A (Ab­stract) (Fiore), 413.

TUMOR REGRESSIONfollowing plasmapheresis in a patient

with advanced cancer of the larynx.temporary restoration of immuneresponse and (Abstract) (Seder, et al],417.

VIRAL DISEASEStransmissionof by plasma protein frac­

tions.jl-Iorowitz & Piet), 503.

WALDENSTROM'S.MACROGLOBULINEMIA

colloid depletion and pleural effusion af­ter plasmapheresis in (Abstract) (Seder& Karlinsky), 415.